Search Results
Your search for it matches 16118 pages
Showing 1851 - 1900The Immune System May Play Vital Role in Remission Duration Among Patients With Multiple Myeloma
Researchers have uncovered the vital role that the immune system may play in determining the duration of remission and progression-free survival in patients with multiple myeloma, according to a recent study published by Coffey et al in Nature Communications. The new findings suggested that the...
Colorectal Cancer Screening: Major Communication Gap in the Clinical Setting
According to the American Cancer Society, colorectal cancer is the second-leading cause of cancer-related death in the United States. In 2023, the disease is expected to cause an estimated 52,550 deaths. Studies show that receiving a clinician recommendation is the strongest and most consistent...
Retrospective Study Reports Tyrosine Kinase Inhibitor Used in CML Associated With Nephrotoxicity
Investigators reported that the tyrosine kinase inhibitor dasatinib, commonly used to treat chronic myeloid leukemia (CML), was associated with nephrotoxicity in 10% of 32 patients with CML being treated with dasatinib in a multicenter, retrospective clinical study conducted to determine the...
ctDNA Identified in Breast Milk From Women With Breast Cancer
Breast milk from women with breast cancer who were diagnosed during pregnancy or postpartum may contain circulating tumor DNA (ctDNA), according to researchers at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. The investigators noted that ctDNA can be detected through liquid biopsy in ...
Study Examines Disparities in Access to Cancer Care Among Non–English-Speaking Patients in the United States
Researchers have revealed that non–English speakers who seek information from hospitals across the United States may face a concerning lack of access to cancer care services, according to a new study published by Chen et al in JNCCN–Journal of the National Comprehensive Cancer Network. Background...
FDA Approves Momelotinib for Patients With Myelofibrosis and Anemia
On September 15, the U.S. Food and Drug Administration (FDA) approved momelotinib (Ojjaara) for the treatment of intermediate- or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post–polycythemia vera and post–essential thrombocythemia), in adults with anemia....
Decentralized Care Models Empower Equitable Pediatric Cancer Treatment
Childhood Cancer Awareness Month is recognized every September to help shine a light on the realities of pediatric cancer and raise awareness of the important work being done to make a difference for the children who are diagnosed with cancer. September 15 also marked the start of Hispanic Heritage ...
AACR Issues Annual Cancer Progress Report
The remarkable progress in medical research—primarily supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI)—over the past 3 decades, coupled with advances in cancer prevention and early detection, has led to a 33% reduction in cancer...
Decentralized Care Models Empower Equitable Pediatric Cancer Treatment
Childhood Cancer Awareness Month is recognized every September to help shine a light on the realities of pediatric cancer and raise awareness of the important work being done to make a difference for the children who are diagnosed with cancer. September 15 also marked the start of Hispanic Heritage ...
Expert Point of View: Priyanka Bhateja, MD
Head and neck cancer specialist Priyanka Bhateja, MD, Assistant Professor in the Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, was encouraged by the findings of the Quarterback trial. As she noted in her comments for The ASCO Post, human papillomavirus...
Quarterback Trial: De-escalation of Chemoradiotherapy for Subset of Patients With HPV-Positive Oropharyngeal Cancer
De-escalation of chemoradiotherapy after induction chemotherapy yields excellent oncologic outcomes in patients with high-risk oropharyngeal cancer associated with the human papillomavirus (HPV). Results of the nonrandomized phase II Quarterback trial suggest that this subset of patients may be...
Expert Point of View: Barbara Burtness, MD
Discussing this study in her Highlights of the Day at the 2023 ASCO Annual Meeting was Barbara Burtness, MD, the Anthony N. Brady Professor of Medicine and Chief Translational Research Officer at Yale Cancer Center, New Haven, Connecticut. She noted that the premise of the FRAIL-IMMUNE trial...
Study Finds Durvalumab Plus Carboplatin and Paclitaxel Effective, Tolerable in Frail Patients With Head and Neck Cancer
As a first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, the PD-L1 inhibitor durvalumab plus weekly carboplatin and paclitaxel provided clinically significant efficacy in the phase II FRAIL-IMMUNE (GORTEC 2018-03) trial.1 This regimen may prove to be an effective...
For Advanced Nasopharyngeal Cancer, Adjuvant Gemcitabine Plus Cisplatin Favored Over Fluorouracil Plus Cisplatin, Study Reports
In patients with N2 and N3 nasopharyngeal carcinoma, adjuvant treatment with concurrent gemcitabine and cisplatin significantly improved progression-free survival, with acceptable toxicity, over fluorouracil plus cisplatin, according to a phase III trial reported from Sun Yat-sen University Cancer...
Expert Point of View: Nabil F. Saba, MD, FACP, and Jennifer Choe, MD, PhD
Nabil F. Saba, MD, FACP, Professor and Vice Chair of Hematology and Medical Oncology, the Lynne and Howard Halpern Chair in Head and Neck Cancer Research, and Director of the HNCA Medical Oncology Program at the Winship Cancer Institute, Emory University, Atlanta, was invited to discuss the...
Head and Neck Cancers 2022–2023 Almanac
Head and neck cancers comprise approximately 4% of all new cancer diagnoses globally and represent approximately 110,000 new cancer diagnoses and 17,000 cancer deaths annually in the United States. Head and neck cancers are a heterogenous group of malignancies where prognosis and treatment varies...
Expert Point of View: Erminia Massarelli, MD, PhD, MS
The invited discussant of the VERSATILE-002 and CUE-101-01 trials, Erminia Massarelli, MD, PhD, MS, said both are examples of a growing interest in evaluating immunotherapeutic strategies and treatment sequences in early-stage head and neck squamous cell cancer as well as in metastatic disease. Dr. ...
Novel HPV-Targeted Agents Boost Efficacy of Pembrolizumab in Head and Neck Cancer, Two Studies Show
Immunotherapeutics that target human papillomavirus (HPV) genotype 16 appear to boost the activity of pembrolizumab in advanced head and neck squamous cell carcinoma. Two examples were presented in posters at the 2023 ASCO Annual Meeting.1,2 The phase II VERSATILE-002 trial evaluated PDS0101,...
First-in-Class Bifunctional Antibody Plus Pembrolizumab Shows Activity in Head and Neck Squamous Cell Carcinoma
The first-in-class bifunctional antibody BCA101—which inhibits both the epidermal growth factor receptor (EGFR) and transforming growth factor-beta (TGF-β)—given with the immune checkpoint inhibitor pembrolizumab, is showing activity and tolerability in recurrent or metastatic head and neck...
Expert Point of View: Glenn J. Hanna, MD and Sherene Loi, MD, PhD
The ASCO Post asked for comment from Glenn J. Hanna, MD, Director of the Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. Dr. Hanna said it is important to put the findings of KEYNOTE-4121 into context...
AEGEAN Trial: Addition of Perioperative Durvalumab to Neoadjuvant Chemotherapy in Resectable NSCLC
The addition of perioperative durvalumab to neoadjuvant chemotherapy may be associated with a tolerable surgical safety profile and may not adversely impact surgery in patients with resectable non–small cell lung cancer (NSCLC), according to new findings presented by Mitsudomi et al at the...
Montefiore Einstein Comprehensive Cancer Center Awarded Comprehensive Designation From the NCI
The newly renamed Montefiore Einstein Comprehensive Cancer Center (MECCC) has been awarded comprehensive designation by the National Cancer Institute (NCI) of the National Institutes of Health. As a result, MECCC was awarded a 5-year, $20 million Cancer Center Support Grant to advance the...
ASCO Updates Guideline on Assessment, Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy
ASCO has updated a guideline on the practical assessment and management of age-associated vulnerabilities in older patients receiving systemic cancer therapy.1 Among the updates, the guideline adds more detail to domains that should be evaluated in geriatric assessments (GAs) and expands patient...
Data Analysis of Young-Onset Lung Cancer Reveals Key Differences Compared With the Disease in Older Adults
Lung cancer, both small cell and non–small cell, is the second most common cancer in both men and women in the United States, with about 238,340 new cases diagnosed each year, and the leading cause of cancer-related mortality, accounting for more than 127,000 deaths annually.1 Lung cancer in...
Atrium Health Levine Children’s Expands to Include New Outpatient Center for Cancer and Blood Disorders
Atrium Health Levine Children’s is expanding its commitment to deliver oncology, hematology, and cellular therapies care to patients across the region, the United States, and the world with the recent opening of its completely reimagined outpatient center. The Torrey Hemby Center for Cancer and...
Quizartinib in Newly Diagnosed FLT3-ITD–Positive Acute Myeloid Leukemia
On July 20, 2023, quizartinib was approved for use with standard cytarabine and anthracycline induction and cytarabine consolidation and as maintenance monotherapy following consolidation chemotherapy in adults with newly diagnosed acute myeloid leukemia that is FLT3 internal tandem duplication...
Incremental Gains Toward Better Outcomes in Small Cell Lung Cancer
Novel treatments beyond the current chemoimmunotherapies are offering more treatment options in small cell lung cancer (SCLC), though real breakthroughs remain elusive, according to Ticiana Leal, MD, Associate Professor in the Department of Hematology and Medical Oncology, Emory University School...
First-in-Class Bifunctional Antibody Plus Pembrolizumab Shows Activity in Head and Neck Squamous Cell Carcinoma
The first-in-class bifunctional antibody BCA101—which inhibits both the epidermal growth factor receptor (EGFR) and transforming growth factor-beta (TGF-β)—given with the immune checkpoint inhibitor pembrolizumab, is showing activity and tolerability in recurrent or metastatic head and neck...
Study Shows Benefit With Addition of Tumor Treating Fields Therapy in Metastatic Non–Small Cell Lung Cancer
Tumor treating fields (TTF) therapy in combination with immune checkpoint inhibition improved overall survival in the pretreated, primarily immunotherapy-naive setting in metastatic non–small cell lung cancer (NSCLC), according to findings from the phase III LUNAR study. These results were...
AI-Based Tool Aids in Diagnosis of Cervical Cancers and Precancers
A new artificial intelligence (AI)-based diagnostic tool for colposcopy examinations may improve the accuracy of diagnosing cancerous and precancerous cervical lesions, including cervical intraepithelial neoplasia (CIN), according to a retrospective validation study presented at the 2023 ASCO...
Predicting Recurrence in Colorectal Cancer Using Postoperative Circulating Tumor DNA Dynamics
Postoperative molecular residual disease detected by circulating tumor DNA (ctDNA) at 4 weeks after resection has emerged as the strongest prognostic risk factor for disease-free survival in patients with resected colorectal cancer. This finding was observed regardless of BRAF V600E status and...
Study Shows Exercise May Improve Sexual Function in Men With Prostate Cancer
It seems that exercise is good for almost everything, including prostate cancer. In fact, exercise had a positive effect on sexual function and enjoyment in men with prostate cancer, according to a recent study presented at the 2023 ASCO Breakthrough meeting by lead study author Daniel Galvão, PhD, ...
Crystal S. Denlinger, MD, FACP, Named New Chief Executive Officer of NCCN
The National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading academic cancer centers—announced Crystal S. Denlinger, MD, FACP, as incoming Chief Executive Officer (CEO). Dr. Denlinger—who is currently NCCN’s Senior Vice President, Chief Scientific Officer—will lead the ...
ASCO Remembers Chemotherapy Pioneer and Karnofsky Award Recipient Irwin H. Krakoff, MD
ASCO is saddened by the passing of Irwin H. Krakoff, MD, on August 9, 2023, at the age of 100. He is remembered as one of the founding fathers of modern chemotherapy. Dr. Krakoff was born on July 20, 1923, in Columbus, Ohio. He attended The Ohio State University, earning his bachelor’s degree in...
Rising After Struggle: Surviving My First ASCO Breakthrough in Japan
After a year of hard work preparing a strong abstract for the prestigious 2023 ASCO Annual Meeting, I finally received an acceptance letter from the scientific committee. I was overjoyed to see the efforts of our multinational team being rewarded. A few moments later, I received the decision...
A Near-Future Look at Medicine When AI Has a Mind of Its Own
“Dr. Hope Kestrel was the only person who knew the patient in Room 132 wasn’t responding to the algorithm-selected treatment. She shuffled forward in the hospital security line, wanting to ger her day started already yet dreading how she’d tell her patient the unexpected and devastating news.” So...
Thomas J. Herzog, MD, Takes Office as President of the GOG Foundation, Inc
Thomas J. Herzog, MD, took office as President of the GOG Foundation (GOG-F, formerly the Gynecologic Oncology Group), Inc, on July 20, 2023, at the NRG Oncology Summer Meeting. Former GOG-F President, Larry J. Copeland, MD, passed the presidential gavel to Dr. Herzog at the GOG-F Board of...
New Updated Edition of a Classic in Hematology Literature
Hematologic malignancies make about 10% of all cancer types in the United States, and the multidisciplinary care of these malignancies has evolved rapidly over the past 20 years. In fact, death rates across all blood cancers have been reduced, and once rapidly fatal diseases such as chronic myeloid ...
Benjamin Besse, MD, PhD, Chooses a Career in Medicine Over Music
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Benjamin Besse, MD, PhD, Professor of Medical Oncology at Paris-Saclay University, Orsay, France, and lung cancer specialist at Gustave Roussy Cancer Campus, Villejuif. Currently, Dr....
There’s an App for That: Digital Health Solutions for Treating Insomnia in Cancer Survivors
Guest Editor’s Note: Insomnia is common in patients with cancer and cancer survivors, and it has significant negative consequences. Cognitive behavior therapy for insomnia (CBT-I) is an effective approach for managing insomnia but is not easily available to many patients. In this installment of The ...
Instinct and Perseverance Helped Save Me From Two Cancers
My intuition about my health has served me well over the past 10 years, possibly even saving my life from two serious cancers. In 2013, I was diagnosed with follicular lymphoma. I believe that my awareness of changes in my body led to its early discovery. One evening, after exercising at the gym...
Vivek Subbiah, MD, Joins SCRI to Advance Early-Phase Clinical Research
Sarah Cannon Research Institute (SCRI) recently announced that Vivek Subbiah, MD, has joined the organization as Chief, Early-Phase Drug Development. In his role, Dr. Subbiah will oversee SCRI’s nine drug development units and lead the expansion of early-phase capabilities and programs across the...
LEAP-017: No Significant Benefit for Lenvatinib Plus Pembrolizumab in Non–MSI-H/dMMR Metastatic Colorectal Cancer
In the final analysis of the phase III LEAP-017 study, the combination of lenvatinib plus pembrolizumab failed to improve outcomes over the standard of care in previously treated patients with metastatic colorectal cancer that lacked high microsatellite instability or mismatch repair deficiency...
Dostarlimab-gxly With Chemotherapy for Endometrial Cancer
On July 31, 2023, the immune checkpoint inhibitor dostarlimab-gxly was approved by the U.S. Food and Drug Administration (FDA) for use with carboplatin and paclitaxel, followed by single-agent dostarlimab, for patients with primary advanced or recurrent endometrial cancer that is mismatch...
Expert Point of View: Martina C. Murphy, MD
Discussant of the ENGOT-EN5/GOG-305/SIENDO trial, Martina C. Murphy, MD, Associate Professor of the Department of Medicine, Division of Hematology, University of Florida, shared insights on the topic of maintenance therapy, its effects on quality of life, and toxicity management. Dr. Murphy...
Vitamin C and D Supplements for Patients With AML Undergoing Intensive Chemotherapy
Patients with acute myeloid leukemia (AML) who received vitamin C and D supplements during intensive chemotherapy had lower rates of complications such as infections, bleeding, and inflammation compared with patients who did not receive the supplements, according to a recent study published by...
ASCO Participates in President’s Cancer Panel Event
ASCO joined the President’s Cancer Panel on September 7, 2023, to highlight the numerous ways ASCO is working to advance the National Cancer Plan and achieve President Biden’s Cancer Moonshot goal of “ending cancer as we know it.” This all-day, virtual event was the first public meeting in support...
Phase III Trial Reports Chemoimmunotherapy Is Superior to Chemotherapy Alone in Malignant Pleural Mesothelioma
Patients with malignant pleural mesothelioma who were treated with a chemoimmunotherapy regimen containing the immune checkpoint inhibitor pembrolizumab experienced significantly improved overall survival compared with those treated with chemotherapy alone, with acceptable tolerability, according...
Can AI Assessment of Screening Mammograms Offer Similar Accuracy to Human Readers?
A commercially available artificial intelligence (AI) algorithm may perform comparably to human readers at assessing screening mammograms, according to a recent study published by Chen et al in Radiology. False-positive interpretations on screening mammograms can result in women without cancer...
Examining Disparities in Endometrial Cancer Outcomes Among Black Patients
Black patients with stage IA low-grade endometrioid endometrial carcinoma may be less likely to undergo a hysterectomy and survive their cancer than White patients with the same type of cancer, according to a recent study published by Taylor et al in Gynecologic Oncology. Background “We’ve known...
